Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Japan Tobacco Inc.    2914   JP3726800000

JAPAN TOBACCO INC.

(2914)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Japan Tobacco : Notice Concerning Amendments to Earnings Forecasts of a Subsidiary

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2020 | 01:24am EDT

FOR IMMEDIATE RELEASE

Tokyo, January 20, 2020

Notice Concerning Amendments to Earnings Forecasts of a Subsidiary

Japan Tobacco Inc. (JT) (TSE: 2914) announces that Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), our subsidiary company, amended its full-year earnings forecasts for the fiscal year ended December 31, 2019 (January 1, 2019 to December 31, 2019) as shown in the attached sheet.

The amendment will not have any material impact on the JT Group's consolidated performance.

(Attachment)

  • Torii Amends Full-Year Earnings Forecasts for Fiscal Year Ended December 31, 2019

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With over 63,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under the Ploom brand and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.

Contact:

Dinesh Babu Thotakura, General Manager

Media and Investor Relations Division

Japan Tobacco Inc.

Tokyo: +81-3-5572-4292

E-mail: jt.media.relations@jt.com

(Reference)

January 20, 2020

Torii Pharmaceutical Co., Ltd.

Torii Amends Full-Year Earnings Forecasts for Fiscal Year ended December 31, 2019

In consideration of the recent trend in earnings and other factors, Torii Pharmaceutical, Co., Ltd. ("Torii") has amended its full-year earnings forecasts for the fiscal year ended December 31, 2019, which were announced on October 31, 2019, as described below.

1. Amendments to Full-Year Earnings Forecasts for Fiscal Year Ended December 31, 2019 (January 1, 2019, to December 31, 2019)

Net sales

Operating

Ordinary

Net income

Net income

income

income

per share

(Millions of

(Millions of

(Millions of

(Millions of

(Yen)

yen)

yen)

yen)

yen)

Previous forecasts (A)

42,700

700

1,000

25,700

915.62

Amended forecasts (B)

42,990

1,430

1,690

27,360

974.71

Variance (B-A)

+290

+730

+690

+1,660

Variance rate (%)

+0.7

+104.3

+69.0

+6.5

(Reference)

Fiscal year ended

62,551

4,951

5,080

1,164

41.51

December 31, 2018

results

2. Amendments Details

Net Sales are expected to increase driven by the positive sales performance of allergen immunotherapy products, CEDARCURE® Japanese Cedar Pollen Sublingual Tablets.

Operating income and ordinary income are expected to exceed the previous forecasts, mainly driven by improved sales cost ratio and cost reduction initiatives which are expected to reduce selling, general and administrative expenses. Additionally, net income is also forecast to be higher as Torii recognized a deferred tax asset, which was not included in the previous forecast.

*The above-mentioned earnings forecasts are based on information available to Torii as of the date of this announcement. Actual business results may differ from the forecast figures herein.

Disclaimer

Japan Tobacco Inc. published this content on 20 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2020 06:23:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JAPAN TOBACCO INC.
03/27JAPAN TOBACCO : Notice of Receipt of Dividend from JT's Consolidated Subsidiary
PU
02/07TORII PHARMACEUTICAL : Progress of the Medium-Term Management Plan 2021 and Revi..
AQ
02/06JAPAN TOBACCO : Introduction of Restricted Stock Remuneration Plan and Performan..
PU
02/06JAPAN TOBACCO INC. : Annual results
CO
02/03JAPAN TOBACCO INC. : annual earnings release
01/28JAPAN TOBACCO : Notice of Financing through Subordinated Loan
PU
01/24JAPAN TOBACCO : JT Receives Manufacturing and Marketing Approval of CORECTIM Oin..
AQ
01/22JAPAN TOBACCO : Japanese Domestic Cigarette Sales Results for December 2019 (Pre..
PU
01/20JAPAN TOBACCO : Notice Concerning Amendments to Earnings Forecasts of a Subsidia..
PU
01/16TORII PHARMACEUTICAL : Signs Exclusive License Agreement with JT for Development..
AQ
More news
Financials (JPY)
Sales 2019 2 166 B
EBIT 2019 510 B
Net income 2019 349 B
Debt 2019 708 B
Yield 2019 7,71%
P/E ratio 2019 10,2x
P/E ratio 2020 11,6x
EV / Sales2019 1,96x
EV / Sales2020 1,90x
Capitalization 3 541 B
Chart JAPAN TOBACCO INC.
Duration : Period :
Japan Tobacco Inc. Technical Analysis Chart | 2914 | JP3726800000 | MarketScreener
Technical analysis trends JAPAN TOBACCO INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 2 468,06  JPY
Last Close Price 1 996,50  JPY
Spread / Highest target 67,8%
Spread / Average Target 23,6%
Spread / Lowest Target -9,34%
EPS Revisions
Managers
NameTitle
Masamichi Terabatake President, CEO & Representative Director
Yasutake Tango Chairman
Naohiro Minami CFO, Representative Director & Executive VP
Hiroyuki Miki Executive Officer, Head-Research & Development
Mutsuo Iwai Director & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
JAPAN TOBACCO INC.0.88%32 410
ALTRIA GROUP, INC.-22.90%71 510
ITC LIMITED-2.23%29 509
PT HANJAYA MANDALA SAMPOERNA TBK-5.54%12 314
KT&G CORPORATION0.65%8 024
PT GUDANG GARAM TBK-4.28%5 746